Drugs / 1018 ISS
1018 ISS
also known as
CpG 1018 · Cpg oligonucleotide 1018 iss · Iss 1018 · Iss 1018 cpg oligodeoxynucleotide
targets TLR9 via activation
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06334393 | Mar 2024 → Apr 2025 | Zika virus infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05606341 | Mar 2023 → Nov 2026 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1 | NCT04830800 | Mar → Jun 2021 | COVID-19, severe acute respiratory syndrome, viral pneumonia | Institute of Vaccines and Medical Biologicals, Vietnam | Completed | No outcome recorded |
| Phase 1 | NCT04177355 | Jan 2020 → Nov 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00426712 | Jan 2006 → Mar 2008 | hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05506969 | Aug 2022 → Oct 2023 | pneumonic plague | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00251394 | Jul 2004 → Dec 2006 | non-Hodgkin lymphoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06366490 Background | Feb → Nov 2026 expected | ovarian carcinoma | PhotonPharma, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04405908 Comparator | Jun 2020 → Oct 2021 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 1/2 | NCT04764422 Comparator | Mar 2021 → Sep 2022 | COVID-19, severe acute respiratory syndrome, viral pneumonia | Mahidol University | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1018ISS | “the last Rituxan infusion is given, a fourth and final 1018ISS injection will be given.” NCT00251394 ↗ |
| Known as | CpG 1018 | “The vaccine series will consist of Innocell cells combined with CpG 1018 adjuvant via intradermal (ID) injection every 2 weeks (14 ± 3 days) x 3 doses.” NCT06366490 ↗7“NDV-HXP-S 1 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM” NCT04764422 ↗ “1 μg +/- CpG1018 (a toll-like receptor 9 agonist)” PMID 35577631 ↗ May 2022 “rF1V vaccine and CpG 1018® adjuvant” NCT05506969 ↗ |
| Known as | Cpg oligonucleotide 1018 iss | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗ |
| Known as | Iss 1018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗ |
| Known as | Iss 1018 cpg oligodeoxynucleotide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗ |
| Action | Activate | “1 μg +/- CpG1018 (a toll-like receptor 9 agonist)” PMID 35577631 ↗ May 2022 |
| Modality | Oligonucleotide (other) | “immunostimulatory phosphorothiolate oligodeoxyribonucleotide, 1018 ISS” NCT00251394 ↗ |
| Route | Subcutaneous | “Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion.” NCT00251394 ↗ |
| Target | TLR9 | “TLR9 agonist” NCT05606341 ↗ |